Plasma hTERT mRNA discriminates between clinically localized and locally advanced disease and is a predictor of recurrence in prostate cancer patients

March-Villalba, J.A.; Martínez-Jabaloyas, J.M.; Herrero, Marí­a José; Santamaria, Jose; Aliño, Salvador F.; Dası́, Francisco

doi:10.1517/14712598.2012.685716

Cited by 17 publications

(19 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18,27,37 In the present study, rigorous efforts to eliminate DNA from samples of RNA, as well as limiting the number of cycles for amplification of hTERT cDNA to prevent false-positive results, might have contributed to diminished sensitivity. 18,27,37 In the present study, rigorous efforts to eliminate DNA from samples of RNA, as well as limiting the number of cycles for amplification of hTERT cDNA to prevent false-positive results, might have contributed to diminished sensitivity.…”

Section: Discussionmentioning

confidence: 94%

“…18 In gastric cancer, 2 studies yielded very different results, namely 100% specificity and 8% sensitivity 36 versus 87% specificity and 66% sensitivity. This observation suggested highly specific diagnostic value (100% specificity), even though sensitivity was relatively low (22%).…”

Section: Discussionmentioning

confidence: 99%

“…4 The use of cfNAs as biomarkers is attractive because samples of plasma and serum ("liquid biopsy") are easy to obtain. Subsequently, the presence has been reported of specific mRNAs in plasma from patients with a variety of cancers, such as cancers of the colon, [12][13][14] breast, 15,16 prostate, 17,18 lung, 19 and thyroid. In addition, studies of the origin and role of cfNAs suggest the ubiquity of cfNAs in the cancer disease 5 and have attracted the attention of many research groups.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Potential clinical significance of perioperative levels of mRNA in plasma from patients with cancer of the larynx or hypopharynx

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Potential clinical significance of perioperative levels of mRNA in plasma from patients with cancer of the larynx or hypopharynx

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In addition, they found that serum hTERT mRNA level was significantly different in different tissues and could be used as a new and useful biomarker for cancer. March et al [18] also detected plasma hTERT mRNA content in 49 patients with prostate cancer and found plasma hTERT mRNA content was significantly higher in patients with locally advanced lesions than in patients with localized lesions. Thus, it can be used as a non-invasive marker of prostate cancer to differentiate patients with locally advanced disease at molecular level.…”

Section: Discussionmentioning

confidence: 99%

Joint quantitative measurement of hTERT mRNA in both peripheral blood and circulating tumor cells of patients with nasopharyngeal carcinoma and its clinical significance

Shen

Wang

et al. 2017

BMC Cancer

View full text Add to dashboard Cite

BackgroundThe study was aimed to quantitatively detect mRNA levels of the catalytic subunit of telomerase (hTERT) in both peripheral blood and circulating tumor cells (CTCs) of patients with nasopharyngeal carcinoma (NPC) and explore its significance in early diagnosis and treatment of NPC.MethodshTERT mRNA levels in peripheral blood and CTCs of 33 NPC patients before and after treatment with intensity-modulated radiation therapy (IMRT) or/and chemotherapy and 24 healthy controls were measured using real-time quantitative PCR (qPCR) and their correlations to clinic pathological factors of NPC were analyzed.ResultsPeripheral hTERT mRNA content was 10.75 ± 4.29 in NPC patients and 0.95 ± 0.37 in control subjects (P < 0.05), and had a significant correlation with patients’ clinical stage, T stage, and N stage (P < 0.05). Treatment of NPC patients at stages I and II with simple IMRT significantly reduced hTERT mRNA level from 5.60 ± 2.33 to 3.43 ± 1.42 (P < 0.05) and treatment of patients at advanced stage (III and IV) with induction chemotherapy followed by IMRT significantly reduced hTERT mRNA levels from 12.68 ± 3.08 to 10.68 ± 2.48 to 3.13 ± 1.69 (P < 0.05), respectively. In addition, the study also showed that hTERT mRNA content in CTCs of NPC patients was 10.65 ± 4.28, evidently higher than that of 1.09 ± 0.40 in control subjects (P < 0.05) and hTERT mRNA level in CTCs of NPC patients was obviously correlated to patients’ clinical stage, T stage and N stage (P < 0.05). After treatment, hTERT mRNA level in CTCs of NPC patients lowered from 10.65 ± 4.28 to 5.59 ± 2.32 (P < 0.05). The correlation analysis found that hTERT mRNA level in peripheral blood and CTCs of NPC patients were highly correlated with a correlation coefficient of 0.981.ConclusionshTERT mRNA levels in peripheral blood and CTCs of NPC patients were significantly enhanced compared to that in healthy controls and highly correlated. Changes in hTERT mRNA level was closely correlated to patients’ clinical stage and T stage. Radiochemotherapy could effectively reduce hTERT mRNA level in peripheral blood and CTCs. Thus, it is possible using the joint detection of hTERT mRNA level in peripheral blood and CTCs as a new biomarker for early diagnosis, treatment efficacy and prognosis of NPC.

show abstract

“…However, the potential clinical value of the detection of cfRNA in plasma did not attract the attention of researchers until 1999, when two parallel studies reported the detection of tyrosinase mRNA in patients with metastatic melanoma122 and mRNA associated with EBV in patients with nasopharyngeal carcinoma 123. Many studies have subsequently reported the presence of specific mRNA in plasma from patients with a variety of cancers including colon,124–126 breast,127,128 prostate,129,130 melanoma,122 lung,131 and thyroid 132…”

Section: Circulating Cell-free Rna (Cfrna)mentioning

confidence: 99%

Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology

González-Masiá¹,

Garcı́a-Olmo²,

García‐Olmo³

2013

OTT

View full text Add to dashboard Cite

The presence of small amounts of circulating nucleic acids in plasma and serum (CNAPS) is not a new finding. The verification that such amounts are significantly increased in cancer patients, and that CNAPS might carry a variety of genetic and epigenetic alterations related to cancer development and progression, has aroused great interest in the scientific community in the last decades. Such alterations potentially reflect changes that occur during carcinogenesis, and include DNA mutations, loss of heterozygosity, viral genomic integration, disruption of microRNA, hypermethylation of tumor suppressor genes, and changes in the mitochondrial DNA. These findings have led to many efforts toward the implementation of new clinical biomarkers based on CNAPS analysis. In the present article, we review the main findings related to the utility of CNAPS analysis for early diagnosis, prognosis, and monitoring of cancer, most of which appear promising. However, due to the lack of harmonization of laboratory techniques, the heterogeneity of disease progression, and the small number of recruited patients in most of those studies, there has been a poor translation of basic research into clinical practice. In addition, many aspects remain unknown, such as the release mechanisms of cell-free nucleic acids, their biological function, and the way by which they circulate in the bloodstream. It is therefore expected that in the coming years, an improved understanding of the relationship between CNAPS and the molecular biology of cancer will lead to better diagnosis, management, and treatment.

show abstract

Plasma hTERT mRNA discriminates between clinically localized and locally advanced disease and is a predictor of recurrence in prostate cancer patients

Abstract: Plasma hTERT mRNA quantification can be both a useful non-invasive tumor marker for discriminating between localized and locally advanced PCa, as well as a prognostic factor of recurrence at the molecular level.

Cited by 17 publications

References 12 publications

Potential clinical significance of perioperative levels of mRNA in plasma from patients with cancer of the larynx or hypopharynx

Potential clinical significance of perioperative levels of mRNA in plasma from patients with cancer of the larynx or hypopharynx

Joint quantitative measurement of hTERT mRNA in both peripheral blood and circulating tumor cells of patients with nasopharyngeal carcinoma and its clinical significance

Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology

Contact Info

Product

Resources

About